DAPT-Shock AMI – Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial InfarctionDAPT-SHOCK-AMI study

EPIDAURUS – Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary syndrome undergoing percutaneoUS coronary intervention

Selution de-novo – A Prospective Randomized, Multi-center, International, Open label, Clinical trialcomparing the SELUTION DEB strategy versus DES strategy

TRICi-HF Studie – TRICuspid Intervention in Heart Failure Trial (Tric-I-HF Trial)

ATTICUS Amendment C – Apixaban for treatment of embolic stroke of undetermined source

DAPT Substudie – National Biomarker / Platelet Function sub-study of DAPT-SHOCK Trial

MiCLASP PMCF Study – Transcatheter Repair of Mitral Regurgitation with Edwards PASCAL Transcatheter Valve Repair System: A European prospective, multicenter Post Market Clinical Follow up.

TriCLASP PMCF Study – Transcatheter Repair of Tricuspid Regurgitation with Edwards PASCALTranscatheter Valve Repair System: A European prospective,multicenter Post‐Market Clinical Follow up

AccuRate Evaluation of Benefit with Optimal medical treatment with or withOut Transcatheter valve repair of PARADOXical low flow low gradient aortic stenosis

AFR-registry – Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech®Atrial Flow Regulator in Heart Failure Patients– THE AFR- AFTER REGISTRY –The AFR- AFteR Registry CIP Version 1.1 final dated 26 May 2020

CAN-Shock – Cangrelor in patients with acute myocardial infarction undergoing PCI after CPR, ventilated and/or with cardiogenic shock (CAN-SHOCK)

Encourage-AF-PCI – EEdoxaban in patients with Non-valvular atrial fibrillation undergoing perCutaneOUs coRonAry intervention – a GErman non-interventional study

Post-Market Registry to Evaluate the Safety and Efficacy of theSUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system in theTreatment of an Octo- and Nonagenarian All-Comer Patient Cohortwith Coronary Artery Disease

Pulmonary Embolism International THrOmbolysis trial:A reduced dose of thrombolytic treatment for patients with intermediatehigh-risk acute pulmonary embolism: a randomized, placebo-controlled trial

Conduct IIT part2 – A prospective identification of procedure related variables associated with permanent pacemaker implantation in patients receiving an Edwards SAPIEN 3 valve via a transfemoral procedure

Impact of acute hemodynamic effects on myocardial remodelling and mid-term durability after transcatheter edge-to-edge repair of mitral regurgitation using PASCAL®

Reveal-Transition – Rivaroxaban – Evaluation of Variables Enhancing Antithrombotic Efficacy and Longterm-Outcome in stabilized patients with cardiovascular disease

TRADE – Transport und Delir bei älteren Menschen - Eine Studie zur Delirreduktion und Verbesserung der Kommunikation an den Schnittstellen durch strukturierte Information und Aktivierung von Vertrauenspersonen und Angehörigen bei Verlegung

COBRA-Reduce – Cobra PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated with Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of strokeand bleeding compared to medical therapy: a prospective randomized clinical trial

Platelets-Translational platform Z03

REVACEPT, A NOVEL INHIBITOR OF PLATELET ADHESION IN PATIENTS WITHSTABLE CORONARY ARTERY DISEASE UNDERGOING ELECTIVEPERCUTANEOUS CORONARY INTERVENTIONS: A PHASE II, MULTICENTRE,RANDOMISED, DOSE-FINDING, DOUBLE-BLIND AND PLACEBO-CONTROLLEDSTUDY

TOMAHAWK – Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation

ARTESiA – Apixaban zur Reduzierung von Thrombo-Embolie bei Patienten mit mittels implantierten Geräten diagnostiziertem subklinischem Vorhofflimmern

ATTICUS – EKG-Substudie

ATTICUS Amendment B – Apixaban for treatment of embolic stroke of undetermined source

AUGUSTUS – An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety ofApixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and AcuteCoronary Syndrome or Percutaneous Coronary Intervention

ELIMINATE-AF – A PROSPECTIVE, RANDOMIZED, OPEN-LABEL,BLINDED ENDPOINT EVALUATION (PROBE)PARALLEL GROUP STUDY COMPARING EDOXABANVS. VKA IN SUBJECTS UNDERGOING CATHETERABLATION OF NON-VALVULAR ATRIALFIBRILLATION (ELIMINATE-AF)

ENTRUST-AF-PCI – Evaluation of the safety and efficacy of an edoxaban-basedcompared to a vitamin K antagonist-based antithrombotic regimenfollowing successful percutaneous coronary intervention (PCI)with stent placement. (EdoxabaN Treatment versus VKA inpatients with AF undergoing PCI)

ENVISAGE TAVI-AF – Edoxaban vs. Standard of Care and their effects on clinical inpatients having undergone transcatheter aortic valve implantation - in atrial fibrillation

ProgressPVL Registry – Prospektive Beobachtung derAortenklappeninsuffizienz nach TAVI und derweitere Verlauf

ETNA-VTE-Europe – Non-Interventional Study on Edoxaban Treatmentin Routine Clinical Practice in Patientswith Venous Thromboembolism in Europe

ATTICUS – Apixaban for treatment of embolic stroke of undetermined source

ODIn-AF Studie – Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran after Pulmonary Vein Isolation for Atrial Fibrillation - The ODIn-AF Study